2013 House Judiciary Hb 1070
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Aldrich FT-IR Collection Edition I Library
Aldrich FT-IR Collection Edition I Library Library Listing – 10,505 spectra This library is the original FT-IR spectral collection from Aldrich. It includes a wide variety of pure chemical compounds found in the Aldrich Handbook of Fine Chemicals. The Aldrich Collection of FT-IR Spectra Edition I library contains spectra of 10,505 pure compounds and is a subset of the Aldrich Collection of FT-IR Spectra Edition II library. All spectra were acquired by Sigma-Aldrich Co. and were processed by Thermo Fisher Scientific. Eight smaller Aldrich Material Specific Sub-Libraries are also available. Aldrich FT-IR Collection Edition I Index Compound Name Index Compound Name 3515 ((1R)-(ENDO,ANTI))-(+)-3- 928 (+)-LIMONENE OXIDE, 97%, BROMOCAMPHOR-8- SULFONIC MIXTURE OF CIS AND TRANS ACID, AMMONIUM SALT 209 (+)-LONGIFOLENE, 98+% 1708 ((1R)-ENDO)-(+)-3- 2283 (+)-MURAMIC ACID HYDRATE, BROMOCAMPHOR, 98% 98% 3516 ((1S)-(ENDO,ANTI))-(-)-3- 2966 (+)-N,N'- BROMOCAMPHOR-8- SULFONIC DIALLYLTARTARDIAMIDE, 99+% ACID, AMMONIUM SALT 2976 (+)-N-ACETYLMURAMIC ACID, 644 ((1S)-ENDO)-(-)-BORNEOL, 99% 97% 9587 (+)-11ALPHA-HYDROXY-17ALPHA- 965 (+)-NOE-LACTOL DIMER, 99+% METHYLTESTOSTERONE 5127 (+)-P-BROMOTETRAMISOLE 9590 (+)-11ALPHA- OXALATE, 99% HYDROXYPROGESTERONE, 95% 661 (+)-P-MENTH-1-EN-9-OL, 97%, 9588 (+)-17-METHYLTESTOSTERONE, MIXTURE OF ISOMERS 99% 730 (+)-PERSEITOL 8681 (+)-2'-DEOXYURIDINE, 99+% 7913 (+)-PILOCARPINE 7591 (+)-2,3-O-ISOPROPYLIDENE-2,3- HYDROCHLORIDE, 99% DIHYDROXY- 1,4- 5844 (+)-RUTIN HYDRATE, 95% BIS(DIPHENYLPHOSPHINO)BUT 9571 (+)-STIGMASTANOL -
(12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al
US 200601 10428A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 de Juan et al. (43) Pub. Date: May 25, 2006 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA (US); A6F 2/00 (2006.01) Signe E. Varner, Los Angeles, CA (52) U.S. Cl. .............................................................. 424/427 (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Correspondence Address: Featured is a method for instilling one or more bioactive SCOTT PRIBNOW agents into ocular tissue within an eye of a patient for the Kagan Binder, PLLC treatment of an ocular condition, the method comprising Suite 200 concurrently using at least two of the following bioactive 221 Main Street North agent delivery methods (A)-(C): Stillwater, MN 55082 (US) (A) implanting a Sustained release delivery device com (21) Appl. No.: 11/175,850 prising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more (22) Filed: Jul. 5, 2005 bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more Related U.S. Application Data bioactive agents Subretinally; and (60) Provisional application No. 60/585,236, filed on Jul. (C) instilling (e.g., injecting or delivering by ocular ion 2, 2004. Provisional application No. 60/669,701, filed tophoresis) one or more bioactive agents into the Vit on Apr. 8, 2005. reous humor of the eye. Patent Application Publication May 25, 2006 Sheet 1 of 22 US 2006/0110428A1 R 2 2 C.6 Fig. -
Us Anti-Doping Agency
2019U.S. ANTI-DOPING AGENCY WALLET CARDEXAMPLES OF PROHIBITED AND PERMITTED SUBSTANCES AND METHODS Effective Jan. 1 – Dec. 31, 2019 CATEGORIES OF SUBSTANCES PROHIBITED AT ALL TIMES (IN AND OUT-OF-COMPETITION) • Non-Approved Substances: investigational drugs and pharmaceuticals with no approval by a governmental regulatory health authority for human therapeutic use. • Anabolic Agents: androstenediol, androstenedione, bolasterone, boldenone, clenbuterol, danazol, desoxymethyltestosterone (madol), dehydrochlormethyltestosterone (DHCMT), Prasterone (dehydroepiandrosterone, DHEA , Intrarosa) and its prohormones, drostanolone, epitestosterone, methasterone, methyl-1-testosterone, methyltestosterone (Covaryx, EEMT, Est Estrogens-methyltest DS, Methitest), nandrolone, oxandrolone, prostanozol, Selective Androgen Receptor Modulators (enobosarm, (ostarine, MK-2866), andarine, LGD-4033, RAD-140). stanozolol, testosterone and its metabolites or isomers (Androgel), THG, tibolone, trenbolone, zeranol, zilpaterol, and similar substances. • Beta-2 Agonists: All selective and non-selective beta-2 agonists, including all optical isomers, are prohibited. Most inhaled beta-2 agonists are prohibited, including arformoterol (Brovana), fenoterol, higenamine (norcoclaurine, Tinospora crispa), indacaterol (Arcapta), levalbuterol (Xopenex), metaproternol (Alupent), orciprenaline, olodaterol (Striverdi), pirbuterol (Maxair), terbutaline (Brethaire), vilanterol (Breo). The only exceptions are albuterol, formoterol, and salmeterol by a metered-dose inhaler when used -
CAS Number Index
2334 CAS Number Index CAS # Page Name CAS # Page Name CAS # Page Name 50-00-0 905 Formaldehyde 56-81-5 967 Glycerol 61-90-5 1135 Leucine 50-02-2 596 Dexamethasone 56-85-9 963 Glutamine 62-44-2 1640 Phenacetin 50-06-6 1654 Phenobarbital 57-00-1 514 Creatine 62-46-4 1166 α-Lipoic acid 50-11-3 1288 Metharbital 57-22-7 2229 Vincristine 62-53-3 131 Aniline 50-12-4 1245 Mephenytoin 57-24-9 1950 Strychnine 62-73-7 626 Dichlorvos 50-23-7 1017 Hydrocortisone 57-27-2 1428 Morphine 63-05-8 127 Androstenedione 50-24-8 1739 Prednisolone 57-41-0 1672 Phenytoin 63-25-2 335 Carbaryl 50-29-3 569 DDT 57-42-1 1239 Meperidine 63-75-2 142 Arecoline 50-33-9 1666 Phenylbutazone 57-43-2 108 Amobarbital 64-04-0 1648 Phenethylamine 50-34-0 1770 Propantheline bromide 57-44-3 191 Barbital 64-13-1 1308 p-Methoxyamphetamine 50-35-1 2054 Thalidomide 57-47-6 1683 Physostigmine 64-17-5 784 Ethanol 50-36-2 497 Cocaine 57-53-4 1249 Meprobamate 64-18-6 909 Formic acid 50-37-3 1197 Lysergic acid diethylamide 57-55-6 1782 Propylene glycol 64-77-7 2104 Tolbutamide 50-44-2 1253 6-Mercaptopurine 57-66-9 1751 Probenecid 64-86-8 506 Colchicine 50-47-5 589 Desipramine 57-74-9 398 Chlordane 65-23-6 1802 Pyridoxine 50-48-6 103 Amitriptyline 57-92-1 1947 Streptomycin 65-29-2 931 Gallamine 50-49-7 1053 Imipramine 57-94-3 2179 Tubocurarine chloride 65-45-2 1888 Salicylamide 50-52-2 2071 Thioridazine 57-96-5 1966 Sulfinpyrazone 65-49-6 98 p-Aminosalicylic acid 50-53-3 426 Chlorpromazine 58-00-4 138 Apomorphine 66-76-2 632 Dicumarol 50-55-5 1841 Reserpine 58-05-9 1136 Leucovorin 66-79-5 -
MMC International BV
M.M.C. International Steroid Substances Steroid Test A Colour Steroid Test B Colour Steroid Test B Colour with UV Light Stanozolol/ Oxandrolone Test Clenbuterol/ Oxymetholone Test Ephedrine Test Alfadolone Orange Yellow Nil - - - Androsterone Orange Yellow White - - - Beclometasone Brown–yellow Orange Nil - - - Betamethasone Orange–brown Pink–Orange Nil - - - Boldenone Base (Equipoise, Ganabol) (pure powder) Warm red after 2 min. Dark Orange after 2 min. Bright Light Orange - - - Boldenone Undecanoate (oil) Dark brownish-red Dark Red Bright Light Orange - - - Boldenone Undecylenate (oil) Orange - Light Brown Dark Orange → Brown Bright Light Orange-Yellow - - - Carbenoxolone (CBX) Orange Yellow Yellow - - - Cholesterol Violet Orange White - - - Clenbuterol (Spiropent, Ventipulmin) - - - - Purple - Dark brown with yellow-green on the Dark brown with yellow-green on the Clomiphene (Androxal, Clomid, Omifin) Nil Dark brown to black No reaction Dark brown to black sides of the ampoule sides of the ampoule Cortisone Orange Yellow Green - - - Desoxycortone Blue–black Yellow Yellow - - - Dexamethasone Yellow Orange–pink Nil - - - Dienestrol Yellow Orange–red Nil - - - Diethylstilbestrol (DES) Orange (→yellow–green) Nil - - - Dimethisterone Brown–green Orange–red Yellow - - - Drostanolone Propionate (Masteron) (oil) Bright green Yellow-Orange Orange - - - Dydrogesterone (Duphaston) - Orange Green-Yellow - - - Enoxolone Orange Yellow Green-Yellow - - - Ephedrine (also for Pseudo- and Nor-Ephedrine) - - - - - Orange Estradiol (Oestradiol) Orange -
207/2015 3 Lääkeluettelon Aineet, Liite 1. Ämnena I Läkemedelsförteckningen, Bilaga 1
207/2015 3 LÄÄKELUETTELON AINEET, LIITE 1. ÄMNENA I LÄKEMEDELSFÖRTECKNINGEN, BILAGA 1. Latinankielinen nimi, Suomenkielinen nimi, Ruotsinkielinen nimi, Englanninkielinen nimi, Latinskt namn Finskt namn Svenskt namn Engelskt namn (N)-Hydroxy- (N)-Hydroksietyyli- (N)-Hydroxietyl- (N)-Hydroxyethyl- aethylprometazinum prometatsiini prometazin promethazine 2,4-Dichlorbenzyl- 2,4-Diklooribentsyyli- 2,4-Diklorbensylalkohol 2,4-Dichlorobenzyl alcoholum alkoholi alcohol 2-Isopropoxyphenyl-N- 2-Isopropoksifenyyli-N- 2-Isopropoxifenyl-N- 2-Isopropoxyphenyl-N- methylcarbamas metyylikarbamaatti metylkarbamat methylcarbamate 4-Dimethyl- ami- 4-Dimetyyliaminofenoli 4-Dimetylaminofenol 4-Dimethylaminophenol nophenolum Abacavirum Abakaviiri Abakavir Abacavir Abarelixum Abareliksi Abarelix Abarelix Abataceptum Abatasepti Abatacept Abatacept Abciximabum Absiksimabi Absiximab Abciximab Abirateronum Abirateroni Abirateron Abiraterone Acamprosatum Akamprosaatti Acamprosat Acamprosate Acarbosum Akarboosi Akarbos Acarbose Acebutololum Asebutololi Acebutolol Acebutolol Aceclofenacum Aseklofenaakki Aceklofenak Aceclofenac Acediasulfonum natricum Asediasulfoni natrium Acediasulfon natrium Acediasulfone sodium Acenocoumarolum Asenokumaroli Acenokumarol Acenocumarol Acepromazinum Asepromatsiini Acepromazin Acepromazine Acetarsolum Asetarsoli Acetarsol Acetarsol Acetazolamidum Asetatsoliamidi Acetazolamid Acetazolamide Acetohexamidum Asetoheksamidi Acetohexamid Acetohexamide Acetophenazinum Asetofenatsiini Acetofenazin Acetophenazine Acetphenolisatinum Asetofenoli-isatiini -
BOARD MEETING AGENDA Meeting Location: Portland State Office Building 800 NE Oregon Street, Portland, OR 97232 June 6-7, 2018 Updated 6.4.18
Oregon Board of Pharmacy BOARD MEETING AGENDA Meeting Location: Portland State Office Building 800 NE Oregon Street, Portland, OR 97232 June 6-7, 2018 Updated 6.4.18 The mission of the Oregon State Board of Pharmacy is to promote, preserve and protect the public health, safety and welfare by ensuring high standards in the practice of pharmacy and by regulating the quality, manufacture, sale and distribution of drugs. Wednesday, June 6, 2018 @ 8:30AM – Conference Rm A Thursday, June 7, 2018 @ 8:30AM – Conference Room A ≈ If special accommodations are needed for you to attend or participate in this Board Meeting, please contact Loretta Glenn at: (971) 673-0001. ≈ WEDNESDAY, JUNE 6, 2018 I. 8:30AM OPEN SESSION, Penny Reher, R.Ph, Presiding A. Roll Call B. Agenda Review and Approval Action Necessary II. Contested Case Deliberation pursuant to ORS 192.690(1) - Not Open to the Public III. EXECUTIVE SESSION – NOT OPEN TO THE PUBLIC, pursuant to ORS 676.175, ORS 192.660 (1) (2) (f) (k). A. Items for Consideration and Discussion: 1. Deliberation on Disciplinary Cases and Investigations 2. Personal Appearances 3. Deficiency Notifications 4. Case Review B. Employee Performance Review pursuant to ORS 192.660(2)(i). IV. OPEN SESSION - PUBLIC MAY ATTEND - At the conclusion of Executive Session, the Board may convene Open Session to begin some of the following scheduled agenda items - time permitting at approximately 3:30PM. V. Approve Consent Agenda* Action Necessary *Items listed under the consent agenda are considered to be routine agency matters and will be approved by a single motion of the Board without separate discussion. -
IN the UNITED STATES DISTRICT COURT for the WESTERN DISTRICT of MISSOURI WESTERN DIVISION UNITED STATES of AMERICA, Plaintiff, V
IN THE UNITED STATES DISTRICT COURT FOR THE WESTERN DISTRICT OF MISSOURI WESTERN DIVISION UNITED STATES OF AMERICA, Plaintiff, Case No. _____________________________ COUNT ONE: All Defendants v. Conspiracy to Manufacture and Distribute Anabolic Steroids AARON VINCENT SCHWEIDLER, (01) 21 U.S.C. §§ 841(a)(1), (b)(1)(E), and 846 [DOB: 10/10/1984] NMT: 10 Years Imprisonment NMT: $500,000 Fine MICHAEL G. PETERS, (02) NLT: 2 Years Supervised Release [DOB: 03/18/1988] Class C Felony SAMUEL C. MILLER IV, (03) COUNT TWO: All Defendants [DOB: 09/04/1986] Conspiracy to Commit Money Laundering 18 U.S.C. § 1956(h) and NMT: 20 Years Imprisonment NMT: $500,000 Fine NICOLE R. LYNE, (04) NMT: 3 Years Supervised Release [DOB: 12/30/1989] Class C Felony Defendants. COUNT THREE: All Defendants Conspiracy to Commit Access Device Fraud 18 U.S.C. §§ 371, 1029(a)(1) NMT: 5 Years Imprisonment NMT: $250,000 Fine NMT: 3 Years Supervised Release Class D Felony COUNTS FOUR, FIVE and SIX: All Defendants Access Device Fraud 18 U.S.C. §§ 1029(a)(1) and 2 NMT: 10 Years Imprisonment NMT: $250,000 Fine NMT: 3 Years Supervised Release Class C Felony Case 4:16-cr-00024-DGK Document 1 Filed 02/02/16 Page 1 of 16 COUNTS SEVEN, EIGHT and NINE: All Defendants Aggravated Identity Theft 18 U.S.C. § 1028A NLT: 2 Years Imprisonment, NMT: $250,000 Fine, NMT: 1 Years Supervised Release Class E Felony Plus $100 Mandatory Special Assessment on Each Count of Conviction FORFEITURE ALLEGATIONS 18 U.S.C. -
Title 21–Food and Drugs
Title 21–Food and Drugs (This book contains part 1300 to End) Part CHAPTER II—Drug Enforcement Administration, Depart- ment of Justice .................................................................. 1301 CHAPTER III—Office of National Drug Control Policy ............ 1401 1 VerDate Mar<15>2010 11:22 May 06, 2014 Jkt 232078 PO 00000 Frm 00011 Fmt 8008 Sfmt 8008 Y:\SGML\232078.XXX 232078 ehiers on DSK2VPTVN1PROD with CFR VerDate Mar<15>2010 11:22 May 06, 2014 Jkt 232078 PO 00000 Frm 00012 Fmt 8008 Sfmt 8008 Y:\SGML\232078.XXX 232078 ehiers on DSK2VPTVN1PROD with CFR CHAPTER II—DRUG ENFORCEMENT ADMINISTRATION, DEPARTMENT OF JUSTICE Part Page 1300 Definitions .............................................................. 5 1301 Registration of manufacturers, distributors, and dispensers of controlled substances ..................... 21 1302 Labeling and packaging requirements for con- trolled substances ................................................ 54 1303 Quotas ..................................................................... 56 1304 Records and reports of registrants .......................... 64 1305 Orders for schedule I and II controlled substances 82 1306 Prescriptions ........................................................... 90 1307 Miscellaneous .......................................................... 102 1308 Schedules of controlled substances ......................... 105 1309 Registration of manufacturers, distributors, im- porters and exporters of list I chemicals .............. 129 1310 Records and reports of listed -
(12) Patent Application Publication (10) Pub. No.: US 2012/0083445 A1 Tseng Et Al
US 20120083445A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2012/0083445 A1 Tseng et al. (43) Pub. Date: Apr. 5, 2012 (54) COMPOSITIONS CONTAINING HC-HA Publication Classification COMPLEX AND METHODS OF USE THEREOF (51) Int. Cl. A 6LX 38/57 (2006.01) (75) Inventors: Scheffer Tseng, Pinecrest, FL (US); A6IPCI2P 2L/027/02 30:2006.O1 8: Hua He, Miami, FL (US) A6IP 9/00 (2006.01) A6IP37/06 2006.O1 (73) Assignee: TissueTech, Inc., Miami, FL (US) C07K I4/8 308: A6IP 29/00 (2006.01) (21) Appl. No.: 13/262,725 (52) U.S. Cl. ... 514/13.3: 530/380: 514/20.3: 435/69.2: 514/18.6 (22) PCT Filed: Apr. 26, 2010 (57) ABSTRACT (86). PCT No.: PCT/US 10/32452 Disclosed herein, in certain embodiments, is an HCHA com S371 (c)(1) plex comprising hyaluronan and a heavy chain of ICI. (2), (4) Date: Dec. 16, 2011 wherein the transfer of the heavy chain of ICI is catalyzed by s 9 TSG-6. Further disclosed herein, in certain embodiments, is O O an HCHA complex comprising hyaluronan and a heavy Related U.S. Application Data chain of ICI, wherein the transfer of the heavy chain of ICI is (60) Provisional application No. 61/267,776, filed on Dec. catalyzed by the TSG-6 like protein. Additionally, disclosed 8, 2009, provisional application No. 61/172,621, filed herein are methods of manufacturing said complex and meth on Apr. 24, 2009. ods of use thereof Patent Application Publication Apr. 5, 2012 Sheet 1 of 14 US 2012/0083445 A1 A A: Ex3 . -
United States Patent Office Patented Jan
3,365,473 United States Patent Office Patented Jan. 23, 1968 1. 3,365,473 133-LOWER ALKYL GONA-4,8(14)-DIEN-3-ONES 178 PROCESS FOR THE PRODUCTION THEREOF David Taub, Metuchen, N.J., assignor to Merck & Co., Inc., Rahway, N.J., a corporation of New Jersey No Drawing. Filed Dec. 28, 1965, Ser. No. 517,128 15 Claims. (CI. 260-397.3) ABSTRACT OF THE DISCLOSURE 10. This invention disclosed herein is concerned with a novel synthesis of novel intermediate compounds useful in the synthesis of known steroids of the estrane series which have utility in the pharmaceutical field as gonadotro phin inhibiting agents and which also have progestational 15 activity. More particularly, this invention relates to a synthesis of 13.6-lower alkylgona-4,8(14)-dien-3-one-17B ol or 17-keto steroids (Compound III), 3-hydroxy-136 lower alkylgona-1,3,5 (10),8(14)-tetraen-17 (3-ol, or 17B keto, 17-acetal or ketal steroids (Compound IV). In this 20 synthesis, 3-alkoxy-17B-lower alkyl-gona-1,3,5 (10),8,14 pentaen-17B-ol is reacted with lithium and liquid am monia thereby forming 3 alkoxy-133-lower alkyl gona 2,5 (10),8(14)-triene-176-ol which, upon acidic hydrolysis, is converted to the corresponding 3-keto A-derivative; the latter compound is reacted with N-bromo-succinimide thereby aromatizing ring A to form 8 (14)-dehydro estradiol or other 13-alkyl analog; catalytic hydrogena tion of the last-named compound produces 8-iso estradiol 30 The starting material, Compound II, may be prepared or other 13-alkyl analog which is reacted with an etherify by the reduction of a 3-hydroxy or substituted oxy-1718 ing agent to from the corresponding 3-alkyl ether; sodium lower alkyl-1,3,5 (10),8,14-pentaen-17f8-ol, 17-keto, or 17 dichromate oxidation of the latter forms 8-isoestrone 3 acetal or ketal (Compound I) with an alkali metal, pref alkyl ether which is reacted with chloranil to form the erably lithium, in liquid ammonia. -
In Accurately Assessing the Development Of
28 . 5 . 84 Official Journal of the European Communities No L 141 / 1 I (Acts whose publication is obligatory) COUNCIL REGULATION (EEC) No 1410/84 of 15 May 1984 temporarily suspending the autonomous Common Customs Tariff duties on a number of industrial products THE COUNCIL OF THE EUROPEAN taken only temporarily with their term of validity COMMUNITIES, fixed to coincide with the interests of Community production , Having regard to the Treaty establishing the Euro pean Economic Community, and in particular HAS ADOPTED THIS REGULATION : Article 28 thereof, Having regard to the draft Regulation submitted by Article 1 the Commission, The autonomous Common Customs Tariff duties Whereas production of the products referred to in for the products listed in the tables annexed to this this Regulation is at present inadequate or non Regulation shall be suspended as the level indicated existent within the Community and producers are in respect of each of them . thus unable to meet the needs of user industries in the Community ; These suspensions shall be valid : Whereas it is in the Community's interest to sus — from 1 July to 31 December 1984 for the prod pend the autonomous Common Customs Tariff ucts listed in Table I , duties only partially in certain cases , due particu — from 1 July 1984 to 30 June 1985 for the prod larly to the existence of Community production , and ucts listed in Table II . to suspend them completely in other cases ; Whereas , taking account of the difficulties involved Article 2 in accurately assessing the development of the economic situation in the sectors concerned in the This Regulation shall enter into force on 1 July near future, these suspension measures should be 1984 .